Published in Int J Clin Pharmacol Ther Toxicol on March 01, 1987
Haemolytic uraemic syndrome and mutations of the factor H gene: a registry-based study of German speaking countries. J Med Genet (2003) 1.92
Oral bioavailability of digoxin is enhanced by talinolol: evidence for involvement of intestinal P-glycoprotein. Clin Pharmacol Ther (2000) 1.61
Intestinal fluid volumes and transit of dosage forms as assessed by magnetic resonance imaging. Aliment Pharmacol Ther (2005) 1.36
Induction of P-glycoprotein by rifampin increases intestinal secretion of talinolol in human beings: a new type of drug/drug interaction. Clin Pharmacol Ther (2000) 1.27
Influence of polymorphisms of ABCB1 and ABCC2 on mRNA and protein expression in normal and cancerous kidney cortex. Pharmacogenomics J (2006) 1.24
Overexpression of sialyltransferase CMP-sialic acid:Galbeta1,3GalNAc-R alpha6-Sialyltransferase is related to poor patient survival in human colorectal carcinomas. Cancer Res (2001) 1.11
The effect of rifampin treatment on intestinal expression of human MRP transporters. Am J Pathol (2000) 1.04
N-acetylation and debrisoquine type oxidation polymorphism in Caucasians--with reference to age and sex. Int J Clin Pharmacol Ther Toxicol (1990) 1.02
Impact of ABCC2 haplotypes on transcriptional and posttranscriptional gene regulation and function. Pharmacogenomics J (2010) 1.01
Coronary artery ligation, early arrhythmias, and determination of the ischemic area in conscious rats. J Pharmacol Methods (1983) 1.01
Genetic influences on baroreflex function in normal twins. Hypertension (2001) 1.01
Interaction between beta-adrenergic receptor stimulation and nitric oxide release on tissue perfusion and metabolism. J Clin Endocrinol Metab (2001) 1.00
Osmosensitive mechanisms contribute to the water drinking-induced pressor response in humans. Neurology (2005) 0.98
Perfusion of human placenta with hemoglobin introduces preeclampsia-like injuries that are prevented by α1-microglobulin. Placenta (2011) 0.93
The classification of antiseptic products to be administered to wounds--another borderline case between medicinal products and medical devices? Int J Clin Pharmacol Ther (2006) 0.92
Polysaccharides isolated from plant cell cultures of Echinacea purpurea enhance the resistance of immunosuppressed mice against systemic infections with Candida albicans and Listeria monocytogenes. Int J Immunopharmacol (1993) 0.91
LC-MS/MS-based quantification of clinically relevant intestinal uptake and efflux transporter proteins. J Pharm Biomed Anal (2013) 0.89
Bioavailability of amoxicillin and clavulanic acid from extended release tablets depends on intragastric tablet deposition and gastric emptying. Eur J Pharm Biopharm (2008) 0.88
Disposition kinetics of metronidazole in children. Eur J Clin Pharmacol (1983) 0.86
Reference tables for the intrasubject coefficient of variation in bioequivalence studies. Int J Clin Pharmacol Ther (1995) 0.85
Improved detection of bacterial central nervous system infections by use of a broad-range PCR assay. J Clin Microbiol (2014) 0.84
Investigation of the anti-inflammatory potential of Aloe vera gel (97.5%) in the ultraviolet erythema test. Skin Pharmacol Physiol (2008) 0.84
Molecular characterisation of linezolid resistance in two vancomycin-resistant (VanB) Enterococcus faecium isolates using Pyrosequencing. Eur J Clin Microbiol Infect Dis (2008) 0.83
Limited effect of systemic beta-blockade on sympathetic outflow. Hypertension (2001) 0.83
Impact of efavirenz on intestinal metabolism and transport: insights from an interaction study with ezetimibe in healthy volunteers. Clin Pharmacol Ther (2012) 0.82
Pharmacokinetic and pharmacodynamic interactions between the immunosuppressant sirolimus and the lipid-lowering drug ezetimibe in healthy volunteers. Clin Pharmacol Ther (2010) 0.82
Mouse interferon-gamma in liposomes: pharmacokinetics, organ-distribution, and activation of spleen and liver macrophages in vivo. J Interferon Res (1989) 0.82
Roflumilast, a once-daily oral phosphodiesterase 4 inhibitor, lacks relevant pharmacokinetic interactions with inhaled salbutamol when co-administered in healthy subjects. Int J Clin Pharmacol Ther (2006) 0.81
Anticholinergic properties of propiverine and its metabolites. Pharmazie (1990) 0.80
Transporter-mediated uptake into cellular compartments. Xenobiotica (2007) 0.80
Polymorphism of the N-acetyltransferase (NAT2), smoking and the potential risk of periodontal disease. Arch Toxicol (2000) 0.80
Pharmacokinetics of Metronidazole in pregnant women. Chemotherapy (1981) 0.80
[Echinococcosis--case report and review of the literature]. Zentralbl Gynakol (1998) 0.79
Drug interactions between the immunosuppressant tacrolimus and the cholesterol absorption inhibitor ezetimibe in healthy volunteers. Clin Pharmacol Ther (2011) 0.79
Fluorimetric study of 2-p-toluidinonaphthalene-6-sulfonate binding to cytoplasmic yeast pyruvate decarboxylase. Hoppe Seylers Z Physiol Chem (1970) 0.79
Compartment-specific gene regulation of the CAR inducer efavirenz in vivo. Clin Pharmacol Ther (2012) 0.79
Five-day continuous infusion of 5-fluorouracil and pulsed folinic acid in patients with metastatic colorectal carcinoma: an effective second-line regimen. Ann Oncol (1997) 0.78
Influence of propiverine on hepatic microsomal cytochrome p450 enzymes in male rats. Drug Metab Dispos (2003) 0.78
Relationship between human genotype and phenotype of N-acetyltransferase (NAT2) as estimated by discriminant analysis and multiple linear regression: 1. Genotype and N-acetylation in vivo. Pharmacogenetics (1997) 0.78
Albumin binding of photobilirubin II. Biochem J (1983) 0.78
Kinetic evidence for two active sites in cytoplasmic yeast pyruvate decarboxylase. Hoppe Seylers Z Physiol Chem (1970) 0.78
Genetic influences on the pharmacokinetics of orally and intravenously administered digoxin as exhibited by monozygotic twins. Clin Pharmacol Ther (2009) 0.78
[Studies on the metabolism of the bladder spasmolytic, propiverin (mictonorm) in humans]. Pharmazie (1988) 0.77
Prediction of metabolic activity from genotype: the gene-dose effect of N-acetyltransferase. Ther Drug Monit (2001) 0.77
[Differential value of various vital stains of corneal endothelium]. Ophthalmologe (1995) 0.77
N-Acetylation phenotyping with sulfamethazine--problems of sampling. Pharmazie (1989) 0.77
[The quantitative identification of metabolites of dihydralazine in the human]. Pharmazie (1988) 0.77
Immunotherapy of murine visceral leishmaniasis with murine recombinant interferon-gamma and MTP-PE encapsulated in liposomes. J Interferon Res (1991) 0.77
Kinetics of propiverine as assessed by radioreceptor assay in poor and extensive metabolizers of debrisoquine. Eur J Drug Metab Pharmacokinet (1994) 0.77
N-acetylator phenotypes in hyperthyroidism. Int J Clin Pharmacol Ther Toxicol (1988) 0.77
Oxidation phenotyping with debrisoquine in Germany (East). Pharmazie (1990) 0.77
Determination of propiverine and its metabolites in rat samples by liquid chromatography-tandem mass spectrometry. J Chromatogr A (2006) 0.77
Tyramine in the assessment of regional adrenergic function. Biochem Pharmacol (2006) 0.77
The effect of oral glucose loads on tissue metabolism during angiotensin II receptor and beta-receptor blockade in obese hypertensive subjects. Horm Metab Res (2006) 0.76
The anticholinergic drug propiverine inhibits the protein kinase C activity in the rat urinary bladder. Pharmazie (2005) 0.76
Effects of interferon-gamma and streptolysin O on hepatic procainamide N-acetyltransferase and various microsomal cytochrome P450-dependent monooxygenases in rats. Immunopharmacol Immunotoxicol (1996) 0.76
Influence of a new virostatic compound on the induction of enzymes in rat liver. Arzneimittelforschung (1975) 0.76
Bioavailability studies of calcium dobesilate--a case of flip-flop kinetics. Pharmazie (1985) 0.76
[Pharmacokinetic problems in clinical practice: role of drug transporters]. Dtsch Med Wochenschr (2009) 0.76
Kidney transplantation improves quality of life. Transplant Proc (1997) 0.76
Pharmacokinetic interactions between isoniazid and theophylline in rats. J Pharm Pharmacol (1992) 0.75
Tiracizine disposition in healthy volunteers with reference to the debrisoquine oxidation phenotype. Br J Clin Pharmacol (1995) 0.75
Hypothalamic neuropeptide release after experimental subarachnoid hemorrhage: in vivo microdialysis study. Acta Neurol Scand (2004) 0.75
N-acetylation and debrisoquine hydroxylation polymorphisms in patients with Gilbert's syndrome. Br J Clin Pharmacol (1991) 0.75
[Recommendations of the scientific council 1968. XII. A wave of new highschool graduates is coming up]. Zahnarztl Mitt (1968) 0.75
[Study of the pharmacokinetics of morphocycline, tetraverine and oxytetracycline]. Farmakol Toksikol (1978) 0.75
[Recommendations for dental radiography methods]. Int Dent J (1978) 0.75
Trichloroethylene vapours do not produce dominant lethal mutations in male mice. Arch Toxicol (1980) 0.75
[Recommendations of the Scientific Council 1968. 8. Teaching capacity]. Zahnarztl Mitt (1968) 0.75
Bioavailability of metronidazole vaginal tablets (Vagimid). Int J Clin Pharmacol Ther Toxicol (1992) 0.75
[Recommendations of the Scientific Council 1968. 13. Model 100]. Zahnarztl Mitt (1968) 0.75
The estimation of drug plasma levels in epileptics. Int J Clin Pharmacol Biopharm (1978) 0.75
Effects of isoniazid on hepatic drug oxidation and N-acetylation capacities in rats. Pharmazie (1992) 0.75
[A documentation for the question of the new generation in dentistry]. Zahnarztl Mitt (1968) 0.75
[Various practical comments on microorbital complications]. Cesk Stomatol (1979) 0.75
[Basic requirements for controlled clinical studies of periodontal diseases]. Int Dent J (1978) 0.75
Problems in the kinetic evaluation of capacity-limited processes by means of the analog computer MEDA 82 T. Int J Clin Pharmacol Biopharm (1978) 0.75
[Enlargement of the sella in primary hypothyroidism]. Z Gesamte Inn Med (1981) 0.75
[Prognosis, chronification and therapeutic relations in unsatisfactorily improved secondary faulty developments with cardiovascular affections]. Psychiatr Neurol Med Psychol (Leipz) (1979) 0.75
[Interpretations and examples of Bugo-Z]. Zahnarztl Mitt (1965) 0.75
[Recommendations of the Scientific Council 1968. XI. It's a long way]. Zahnarztl Mitt (1968) 0.75
[Antibody response to hemagglutinin and neuraminidase induced by an influenza subunit vaccine (author's transl)]. Zentralbl Bakteriol Orig A (1979) 0.75
[Caffeine-stimulated lipolysis in relation to pathologic pregnancy]. Zentralbl Gynakol (1976) 0.75
[Introduction of a model in industrial medicine--data utilization in occupational medicine]. Zentralbl Arbeitsmed Arbeitsschutz Prophyl Ergonomie (1980) 0.75
[Recommendations of the Scientific Council 1968. X. Fewer medical students--more dental students]. Zahnarztl Mitt (1968) 0.75
[Classification of epidemiological studies of dental caries and definitions of related terms]. Int Dent J (1976) 0.75
[Recommendations of the Scientific council. XIV. The "front" has spoken]. Zahnarztl Mitt (1969) 0.75
[Recommendations of the Scientific Council 1968. With optimism toward the future]. Zahnarztl Mitt (1969) 0.75
[Recommendations for the handling of mercury]. Int Dent J (1978) 0.75
[Unilateral exophthalmos and arteriovenous aneurysm in the region of the Sylvian vessel group in an infant]. Klin Monbl Augenheilkd (1967) 0.75
[Recommendation of the Scientific Council 1968. V. All provinces must cooperate]. Zahnarztl Mitt (1968) 0.75
[Electronic data processing as an aid in occupational medicine documentation - methods, experiences, perspectives]. Zentralbl Arbeitsmed Arbeitsschutz Prophyl Ergonomie (1982) 0.75
A bioequivalence study on retarded formulations of carbamazepine tablets. Int J Clin Pharmacol Ther Toxicol (1992) 0.75